GSK has announced positive results from Phase III clinical trials of depemokimab, a treatment for severe asthma with type 2 inflammation.

The company reports that the trials met the 52-week target for reducing asthma exacerbations, and showed similar rates of adverse events between depemokimab and placebo.

Depemokimab, administered twice a year, targets interleukin-5 (IL-5) to reduce inflammation.

Full results will be presented at a scientific congress and used for regulatory submissions. Depemokimab is not yet approved, GSK adds.

Copyright (c) 2024 CercleFinance.com. All rights reserved.